BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has informed the Exchange regarding National Company Law Appellate Tribunal, New Delhi Order.

Bafna Pharmaceuticals Limited has informed the Exchange that this is in continuation of earlier intimation dated February 05,2019 regarding resolution plan which was approved by NCLT, Chennai vide its order dated February 01, 2019 under the Provisions of IBC, 2016. Pursuant to the Resolution Plan a capital reduction is proposed and the capital of the fully paid up equity shareholders shall be reduced to 10% and consequently the existing 2.36 Crores number of shares shall be reduced to 0.236 Crores.

Bafna Pharmaceuticals Limited has informed the Exchange regarding "Supervision of the Resolution Plan".

Bafna Pharmaceuticals Limited has informed the Exchange regarding Update on CIRP/NCLT Order approving Resolution Plan.

Bafna Pharmaceuticals Limited has informed the Exchange that Mr. Radhakrishnan Dharmarajan has been appointed as Resolution Professional (RP) and Mr. Gopalsamy Ganesh Babu has been relieved as IRP vide Order Passed by National Company Law Tribunal, Single Bench, Chennai dated October 11, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.